GLP-1 and GIP/GLP-1 receptor agonists are being explored for CF patients, with potential to improve pulmonary function through anti-inflammatory and metabolic mechanisms beyond glycemic control.
Lungs + metabolismGLP-1 drugs may address both CFRD diabetes and pulmonary decline through shared inflammatory and metabolic mechanisms
What the researchers found
GLP-1 and GIP/GLP-1 agonists may improve CF pulmonary function through glycemic control, anti-inflammatory effects, weight management, and potential direct airway effects, warranting CF-specific clinical trials.
Why it matters
CFRD accelerates lung decline in CF. GLP-1 drugs that address both diabetes and inflammation could slow lung deterioration.
How the study worked
Review of GLP-1/GIP RA evidence relevant to cystic fibrosis pulmonary function, covering metabolic, inflammatory, and airway mechanisms.
What this study cannot tell us
No CF-specific GLP-1 trial data. Extrapolated from T2D and general population studies. CF lung pathophysiology is unique.
How to read the evidence
Review with mechanistic rationale. No CF-specific clinical data yet.
When this study was published
Published in 2025.
The bigger picture
If GLP-1 drugs improve CF lung function, they could become standard care for the growing population of CF patients surviving into adulthood with metabolic complications.
Questions still open
- Would a GLP-1 drug trial in CF show improved FEV1?
- Do GLP-1 receptors exist on CF airway epithelium?
- Could GIP co-agonism provide extra benefit in CF?
Common questions
Could GLP-1 drugs help CF patients' lungs?
Why would a diabetes drug help CF lungs?
Read the original research
Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass index.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 25(1), 70-77
Citation
Horvit, Andrew; Kaput, Katie; Neece, Amber; Abramowitz, Jessica; Abreu, Marconi; Ratti, Gregory A; Finklea, James D; Jain, Raksha; Mirfakhraee, Sasan. (2026). Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass index.. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 25(1), 70-77. https://doi.org/10.1016/j.jcf.2025.10.006